Dalton Helps Duke-NUS Achieve Clinical Milestone

Dalton Pharma Services has successfully completed a comprehensive drug development program for the CELADEN trial, which included Celgosivir process development, cGMP API and capsule manufacturing in support of Duke-NUS’s clinical research program.
 
The Phase Ib trial to evaluate Celgosivir as a treatment for Dengue has opened for enrolment following the successful completion of API development and manufacture of the final dosage form by Dalton Pharma Services.
 
“We are pleased to have reached this important milestone with the support of Dalton Pharma Services,” said Dr. Cynthia Sung, project manager for the CELADEN trial. “They were able to develop the active ingredient and produce GMP clinical materials, which helped us to get it into the clinic for this important trial. Their integrated approach and experience in moving early stage projects forward really streamlined the process for us.”
 
“We are very grateful for the opportunity to contribute to the progress of this key project with our customer Duke-NUS. Dalton hopes to continue to support Duke-NUS in their ongoing efforts to bring important new medicines to the world,” said Peter Pekos, chief executive officer of Dalton Pharma Services.